Sanofi Buys Biotech Startup Tidal Therapeutics for Initial $160 Million
April 09 2021 - 2:31PM
Dow Jones News
By Colin Kellaher
Sanofi SA on Friday said it has acquired Tidal Therapeutics, a
preclinical-stage biotech startup using a novel mRNA-based approach
for in-vivo reprogramming of immune cells, for an initial $160
million.
The Paris pharmaceutical giant said it could make up to an
additional $310 in milestone payments as part of the deal, which it
said expands its research capabilities in immuno-oncology and
inflammatory diseases.
Sanofi said Tidal, based in Cambridge, Mass., uses a technology
based on proprietary nanoparticles that deliver mRNA to reprogram
immune cells inside the body. Tidal's current preclinical programs
include in-vivo reprogramming of T-cells or other types of immune
cells for cancer indications.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 09, 2021 14:16 ET (18:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
